Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Oncol Rep ; 36(2): 613-25, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27278244

ABSTRACT

Hepatocellular carcinoma (HCC) is the most common liver malignancy and a leading cause of cancer-related mortality worldwide. Accurate detection and differential diagnosis of early HCC can significantly improve patient survival. Currently, detection of HCC in clinical practice is performed by diagnostic imaging techniques and determination of serum biomarkers, most notably α-fetoprotein (AFP), fucosylated AFP and des-γ-carboxyprothrombin. However, these methods display limitations in sensitivity and specificity, especially with respect to early stages of HCC. Recently, high-throughput technologies have elucidated many new pathways involved in hepatocarcinogenesis and have led to the discovery of a plethora of novel, non-invasive serum biomarkers. In particular, the combination of AFP with these new candidate molecules has yielded promising results. In this review, we aimed at recapitulating the most recent (2013-2015) developments in HCC biomarker research. We compared promising novel diagnostic serum protein biomarkers, such as annexin A2, the soluble form of the receptor tyrosine kinase Axl and thioredoxin, as well as their combinations with AFP. High diagnostic performance (area under the curve >0.75) as shown by threshold-independent receiver operating characteristic curve analysis was a prerequisite for inclusion in this review. In addition, we discuss the role and potential of microRNAs in HCC diagnosis and associated methodological challenges.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/metabolism , Liver Neoplasms/diagnosis , Liver Neoplasms/metabolism , Animals , Diagnostic Imaging/methods , Humans , MicroRNAs/metabolism , ROC Curve
2.
Hepatology ; 61(3): 930-41, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25251599

ABSTRACT

UNLABELLED: In hepatocellular carcinoma (HCC), intrahepatic metastasis frequently correlates with epithelial to mesenchymal transition (EMT) of malignant hepatocytes. Several mechanisms have been identified to be essentially involved in hepatocellular EMT, among them transforming growth factor (TGF)-ß signaling. Here we show the up-regulation and activation of the receptor tyrosine kinase Axl in EMT-transformed hepatoma cells. Knockdown of Axl expression resulted in abrogation of invasive and transendothelial migratory abilities of mesenchymal HCC cells in vitro and Axl overexpression-induced metastatic colonization of epithelial hepatoma cells in vivo. Importantly, Axl knockdown severely impaired resistance to TGF-ß-mediated growth inhibition. Analysis of the Axl interactome revealed binding of Axl to 14-3-3ζ, which is essentially required for Axl-mediated cell invasion, transendothelial migration, and resistance against TGF-ß. Axl/14-3-3ζ signaling caused phosphorylation of Smad3 linker region (Smad3L) at Ser213, resulting in the up-regulation of tumor-progressive TGF-ß target genes such as PAI1, MMP9, and Snail as well as augmented TGF-ß1 secretion in mesenchymal HCC cells. Accordingly, high Axl expression in HCC patient samples correlated with elevated vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong phosphorylation of Smad3L, and lower survival. In addition, elevated expression of both Axl and 14-3-3ζ showed strongly reduced survival of HCC patients. CONCLUSION: Our data suggest that Axl/14-3-3ζ signaling is central for TGF-ß-mediated HCC progression and a promising target for HCC therapy.


Subject(s)
Autocrine Communication , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Proto-Oncogene Proteins/physiology , Receptor Protein-Tyrosine Kinases/physiology , Signal Transduction , Transforming Growth Factor beta/physiology , 14-3-3 Proteins/physiology , Carcinoma, Hepatocellular/mortality , Cell Movement , Epithelial-Mesenchymal Transition , Female , Humans , Liver Neoplasms/mortality , Male , Neoplasm Invasiveness , Phosphatidylinositol 3-Kinases/physiology , Signal Transduction/physiology , Axl Receptor Tyrosine Kinase
3.
Int J Cancer ; 137(2): 385-394, 2015 Jul 15.
Article in English | MEDLINE | ID: mdl-25529751

ABSTRACT

If diagnosed at early stages, patients with hepatocellular carcinoma (HCC) can receive curative therapies, whereas therapeutic options at later stages are very limited. Here, we addressed the potential of soluble Axl (sAxl) as a biomarker of early HCC by analyzing levels of sAxl in 311 HCC and 237 control serum samples from centers in Europe and China. Serum concentrations of sAxl were significantly increased in HCC (18.575 ng/mL) as compared to healthy (13.388 ng/mL) or cirrhotic (12.169 ng/mL) controls. Receiver operating characteristic curve analysis of sAxl in very early stage HCC patients (BCLC 0) showed an area under the curve (AUC) of 0.848, with a sensitivity of 76.9% and a specificity of 69.2%. α-Fetoprotein (AFP)-negative HCC patients displayed an AUC of 0.803, with sensitivity and specificity of 73% and 70.8%. Combination of sAxl and AFP improved diagnostic accuracy to 0.936 in very early HCC patients and to 0.937 in all HCC. Differential diagnosis of very early HCC versus liver cirrhosis showed a combined performance for sAxl and AFP of 0.901 with a sensitivity of 88.5% and a specificity of 76.7%. Furthermore, sAxl levels failed to be elevated in primary ovarian, colorectal and breast carcinomas as well as in secondary hepatic malignancies derived from colon. In summary, sAxl outperforms AFP in detecting very early HCC as compared to healthy or cirrhotic controls and shows high diagnostic accuracy for AFP-negative patients. sAxl is specific for HCC and suggested as a biomarker for routine clinical use.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Hepatocellular/diagnosis , Liver Neoplasms/diagnosis , Proto-Oncogene Proteins/blood , Receptor Protein-Tyrosine Kinases/blood , Biomarkers, Tumor/metabolism , Carcinoma, Hepatocellular/blood , Cell Line, Tumor , Diagnosis, Differential , Early Diagnosis , Enzyme-Linked Immunosorbent Assay , Female , Hep G2 Cells , Humans , Kaplan-Meier Estimate , Liver Cirrhosis/blood , Liver Cirrhosis/diagnosis , Liver Neoplasms/blood , Male , Middle Aged , Neoplasm Staging , Proto-Oncogene Proteins/metabolism , ROC Curve , Receptor Protein-Tyrosine Kinases/metabolism , Solubility , alpha-Fetoproteins/metabolism , Axl Receptor Tyrosine Kinase
4.
PLoS One ; 8(9): e74924, 2013.
Article in English | MEDLINE | ID: mdl-24040362

ABSTRACT

Deregulated Rho GTPases Rac1 and Cdc42 have been discovered in various tumors, including prostate and Rac protein expression significantly increases in prostate cancer. The Rac and Cdc42 pathways promote the uncontrolled proliferation, invasion and metastatic properties of human cancer cells. We synthesized the novel compound AZA1 based on structural information of the known Rac1 inhibitor NSC23766. In the current study we investigated the effects of inhibition of these pathways by AZA1 on prostate tumorigenicity by performing preclinical studies using a xenograft mouse model of prostate cancer. In androgen-independent prostate cancer cells, AZA1 inhibited both Rac1 and Cdc42 but not RhoA GTPase activity in a dose-dependent manner and blocked cellular migration and proliferation. Cyclin D1 expression significantly decreased following Rac1/Cdc42 inhibition in prostate cancer cells. AZA1 treatment also down-regulated PAK and AKT activity in prostate cancer cells, associated with induction of the pro-apoptotic function of BAD by suppression of serine-112 phosphorylation. Daily systemic administration of AZA1 for 2 weeks reduced growth of human 22Rv1 prostate tumor xenografts in mice and improved the survival of tumor-bearing animals significantly. These data suggest a role of AZA1 in blocking Rac1/Cdc42-dependent cell cycle progression, cancer cell migration and increase of cancer cell apoptosis involving down-regulation of the AKT and PAK signaling pathway in prostate cancer cells. We therefore propose that a small-molecule inhibitor therapy targeting Rac1/Cdc42 Rho GTPase signaling pathways may be used as a novel treatment for patients with advanced prostate cancer.


Subject(s)
Antineoplastic Agents/pharmacology , GTPase-Activating Proteins/antagonists & inhibitors , Indoles/pharmacology , Phosphoproteins/antagonists & inhibitors , Prostatic Neoplasms/metabolism , Pyrimidines/pharmacology , rac1 GTP-Binding Protein/antagonists & inhibitors , Actins/metabolism , Aminoquinolines/chemistry , Animals , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Movement , Cell Proliferation , Cytoskeleton/metabolism , Dose-Response Relationship, Drug , GTPase-Activating Proteins/metabolism , Humans , Indoles/chemistry , Male , Mice , Neoplasm Invasiveness , Neoplasm Metastasis , Phosphoproteins/metabolism , Prostatic Neoplasms/drug therapy , Pyrimidines/chemistry , Xenograft Model Antitumor Assays , rac1 GTP-Binding Protein/metabolism
5.
Curr Pharm Des ; 18(27): 4135-47, 2012.
Article in English | MEDLINE | ID: mdl-22630087

ABSTRACT

Hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) represent the majority of hepatic malignancies and are among the most frequent causes of cancer deaths worldwide with a rising incidence in western countries. Upon progression of liver cancer, the epithelial to mesenchymal transition (EMT) is considered a key process that drives intrahepatic metastasis. EMT is the transformation of epithelial cells to a mesenchymal phenotype exacerbating motility and invasiveness of various epithelial cell types. In this review we focus on EMT in hepatic fibrosis, HCC and CCC that is governed by the transforming growth factor (TGF)-ß signaling. This cytokine has been shown to play diverse and conflicting roles in malignant development, acting as a tumor-suppressor in early cancerogenesis but enhancing tumor dissemination in later stages of tumor progression. Importantly, TGF-ß can induce EMT in a variety of cancers including HCC and CCC, even though the complex molecular mechanisms underlying this process are not yet fully understood. We aim at collecting recent findings on the impact of TGF-ß-induced EMT in liver carcinoma progression and at discussing new insights on promising drugable targets for future therapeutic approaches against CCC and HCC.


Subject(s)
Epithelial-Mesenchymal Transition/physiology , Liver Neoplasms/pathology , Transforming Growth Factor beta/metabolism , Animals , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/pathology , Cholangiocarcinoma/epidemiology , Cholangiocarcinoma/pathology , Disease Progression , Humans , Liver Cirrhosis/pathology , Liver Neoplasms/epidemiology , Neoplasm Metastasis , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...